Chunlai Feng
Overview
Explore the profile of Chunlai Feng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
395
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yu D, Gu J, Zhang J, Wang M, Ji R, Feng C, et al.
ACS Nano
. 2025 Mar;
PMID: 40059332
Neutrophil-derived extracellular vesicles (NEVs) are critically involved in disease progression and are considered potential biomarkers. However, the tedious processes of NEV separation and detection restrain their use. Herein, we presented...
2.
Rui M, Su Y, Tang H, Li Y, Fang N, Ge Y, et al.
AAPS PharmSciTech
. 2025 Feb;
26(2):61.
PMID: 39934607
Study explored the synergistic anti-tumor effects of a combination of compounds from Traditional Chinese Medicine, including rosmarinic acid (RA), chlorogenic acid (CA), and scoparone (SCO), in the formulation of multivesicular...
3.
Yang M, Han X, Li H, Du F, Feng C, Gong A
J Cancer
. 2025 Feb;
16(4):1101-1117.
PMID: 39895794
Glioblastoma multiforme (GBM), whose pathogenesis involves proneural-to-mesenchymal transition (PMT), is the most malignant type of glioma and is associated with a bleak prognosis. Lactate dehydrogenase (LDH) comprises two major subunits,...
4.
Sun C, Cai X, Zhong H, Lu Y, Li Y, Cai Y, et al.
Microbiol Spectr
. 2025 Jan;
13(3):e0294524.
PMID: 39878524
The incidence of invasive pulmonary aspergillosis (IPA) in non-neutropenic patients is increasing. This study aimed to evaluate the clinical outcomes and risk factors for mortality in non-neutropenic IPA patients. We...
5.
Feng C, Cheng J, Sun M, Qiao C, Feng Q, Fang N, et al.
Front Pharmacol
. 2025 Jan;
15():1522787.
PMID: 39840098
Introduction: The L. (PVL) and Hand.-Mazz. (TH) herb pair, which is commonly used in traditional Chinese medicine (TCM), has been applied for the treatment of breast cancer. Although its efficacy...
6.
Zhou R, Qin Y, Hu S, Xu Y, Feng C
Future Oncol
. 2024 Nov;
20(40):3471-3476.
PMID: 39607005
Background: This study analyzed the application of dual bronchodilators in patients with non-small cell lung cancer (NSCLC) & chronic obstructive pulmonary disease (COPD) during the perioperative period. Research Design And...
7.
Ji W, She S, Qiao C, Feng Q, Rui M, Xu X, et al.
Front Pharmacol
. 2024 Sep;
15:1465890.
PMID: 39295942
Background: The identification of compound-protein interactions (CPIs) is crucial for drug discovery and understanding mechanisms of action. Accurate CPI prediction can elucidate drug-target-disease interactions, aiding in the discovery of candidate...
8.
He Q, Cao J, Zhang M, Feng C
Front Cell Infect Microbiol
. 2024 Aug;
14:1402888.
PMID: 39176263
Background: The purpose of this study was to investigate the diagnostic value of IL-17 detection in bronchoalveolar lavage fluid (BALF) and plasma samples from nonneutropenic patients with invasive pulmonary aspergillosis....
9.
Jing C, Ding Y, Zhou J, Zhang Q, Wang M, Ou Q, et al.
iScience
. 2024 Jul;
27(7):110218.
PMID: 38993672
Timely adjustments of antibiotic and corticosteroid treatments are vital for patients with diffuse parenchymal lung diseases (DPLDs). In this study, 41 DPLD patients with negative metagenomic next-generation sequencing (mNGS) results...
10.
Feng C, Qiao C, Ji W, Pang H, Wang L, Feng Q, et al.
Int J Biol Macromol
. 2024 Jun;
274(Pt 1):133263.
PMID: 38901515
The enzyme 15-hydroxyprostaglandin dehydrogenase (15-PGDH), which acts as a negative regulator of prostaglandin E2 (PGE2) levels and activity, represents a promising pharmacological target for promoting liver regeneration. In this study,...